Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

← Go back

Full NameDr Aideen Ryan

Pharmacology & Therapeutics

University of Galway

Webpage:nuigalway.ie

Email hidden; Javascript is required.

Research Fields

infectious disease and the immune system
cell and developmental biology/regenerative medicine
cancer/oncology

Postgrad Medical Specialties

Medicine

Medical Subspecialties

Gastroenterology
Haematology
Immunology
Pharmacology

My Work

Dr Aideen Ryan’s research group is focussed on identifying therapeutically targetable stromal cell mediated mechanisms of immune suppression in the tumour microenvironment with a view to enhancing anti-tumour immune responses, and improve therapeutic outcomes in cancer. As part of the larger immunology group at the Regenerative Medicine Institute, Dr Ryan’s research group has significant experience in tumour immunology, stromal cell immunology and evaluation of immune responses in pre-clinical tumour and allogeneic transplantation models. Current research is funded by Science Foundation Ireland, Irish Cancer Society and Industry-funded collaborations (Janssen and AbbVie).

Some of our key discoveries in the past include: Identification of the role of Fas ligand in immune suppression in a pre-clinical model of colon cancer; Identification of the effect of stromal cell differentiation on immune-regulatory ligand expression and host immune responses in vivo, and characterization of the role of NF-κB in the molecular regulation of colon cancer metastasis and host anti-tumour immunity in vivo.